Solórzano SF

Language: Spanish
References: 8
Page: 81-82
PDF size: 146.91 Kb.

Text Extraction

No abstract

REFERENCES

1. CDC. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction— eight states,1998–2005. MMWR 2008;57:144-148. Disponible en: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5706a2.htm

2. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-1463.

3. Temime L, Boelle PY, Opatoswki L, Guillemot D. Impact of capsular switch on invasive pneumococcal disease incidence in a vaccinated population. PLoS One 2008;3:e3244. doi:10.1371/journal.pone.0003244.

4. Silva-Rosales NA, Tene CE, Cervantes-Kardash, Del Toro M. Comparación de la respuesta inmunológica frente a cepas de S. pneumoniae, evaluada por hemaglutinación, en niños inmunizados con vacuna neumocócica heptavalente (dos primovacunaciones con o sin refuerzo). Bol Med Hosp Infant Mex 2012;69:97-103.

5. Scott P, Rutjes AW, Bermetz L, Robert N, Scott S, Lourenço T, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and metaanalysis. Vaccine 2011;29:9711-9721.

6. Fritzell B, Fletcher MA. Pneumococcal polysaccharide-protein (CRM197) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule. Expert Rev Vaccines 2011;10:263-290.

7. Andrews N, Waight PA, Borrow R, Ladhani S, George RC, Slack MP, et al. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLos One 2011;6:e28435. doi:10.1371/journal.pone.0028435.

8. Ota MO, Akinsola A, Townend J, Antonio M, Enwere G, Nsekpong D, et al. The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine 2011;29:2999-3007.